GlassScriptPhysician profile
Joseph J Farris
NPI 1952321804
$1,810.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $213 · 2021: $175 · 2022: $420 · 2023: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.04 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.57 | 2020-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $178.90 | 2021-2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $170.43 | 2022-2023 | Rexulti, Abilify Maintena |
| Vertical Pharmaceuticals, LLC | $169.36 | 2019-2020 | |
| Corium, LLC | $154.33 | 2021-2023 | Azstarys |
| Tris Pharma INC | $121.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $98.68 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $75.74 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $75.32 | 2022-2023 | Ingrezza |
| Shire North American Group INC | $58.71 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.90 | 2022-2023 | Caplyta |
| Alkermes, INC. | $30.78 | 2023 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $28.74 | 2022-2023 | Austedo |
| Ironshore Pharmaceuticals INC. | $28.62 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $17.52 | 2019 | |
| Alfasigma USA, INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.